In vitro pharmacoregulation of CC chemokine ligand 5 and its receptor CCR5 in diffuse lung diseases
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
14514472
PubMed Central
PMC1781614
DOI
10.1080/09629350310001599657
PII: ND1QJKHLL7GV6WRP
Knihovny.cz E-resources
- MeSH
- Bronchoalveolar Lavage Fluid cytology MeSH
- Chemokine CCL5 MeSH
- Chemokines, CC genetics metabolism MeSH
- Cyclosporine pharmacology MeSH
- Dexamethasone pharmacology MeSH
- Adult MeSH
- Glucocorticoids pharmacology MeSH
- Immunosuppressive Agents pharmacology MeSH
- Enzyme Inhibitors pharmacology MeSH
- Cells, Cultured MeSH
- Leukocytes cytology drug effects immunology metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- RNA, Messenger metabolism MeSH
- Pentoxifylline pharmacology MeSH
- Lung Diseases metabolism pathology MeSH
- Receptors, CCR5 genetics metabolism MeSH
- Aged MeSH
- Tumor Necrosis Factor-alpha pharmacology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- CCL5 protein, human MeSH Browser
- Chemokine CCL5 MeSH
- Chemokines, CC MeSH
- Cyclosporine MeSH
- Dexamethasone MeSH
- Glucocorticoids MeSH
- Immunosuppressive Agents MeSH
- Enzyme Inhibitors MeSH
- RNA, Messenger MeSH
- Pentoxifylline MeSH
- Receptors, CCR5 MeSH
- Tumor Necrosis Factor-alpha MeSH
BACKGROUND: CC chemokine ligand (CCL)5 and its receptor CCR5 contribute to leukocyte migration into lungs of patients with diffuse lung diseases (DLD). Pharmacological regulation of CCL5 and CCR5 expression was therefore explored in bronchoalveolar cells obtained from patients with DLD. METHODS: Cells from 21 patients were co-cultivated in vitro with tumour necrosis factor-alpha and dexamethasone, cyclosporin A (CyA) or pentoxifylline. Chemokine mRNA expression and protein production was assessed by reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. RESULTS: Dexamethasone altered CCL5 mRNA expression and suppressed its protein levels. CyA inhibited chemokine mRNA expression but not protein production. Pentoxifylline did not affected chemokine expression. Both dexamethasone and CyA suppressed CCR5 mRNA transcripts. CONCLUSION: In conclusion, while dexamethasone downregulates the CCL5 functional form, CyA and pentoxifylline have no effects on CCL5 protein. These data provide in vitro correlation for clinical applications of immunomodulators in therapy of DLD.
See more in PubMed
J Hum Virol. 1999 Sep-Oct;2(5):270-82 PubMed
Respir Med. 1999 Jan;93(1):52-7 PubMed
Acta Univ Palacki Olomuc Fac Med. 1999;142:23-8 PubMed
Acta Univ Palacki Olomuc Fac Med. 1999;142:127-34 PubMed
Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):1075-80 PubMed
Mediators Inflamm. 2000;9(3-4):169-74 PubMed
Immunol Lett. 2002 Mar 1;80(3):189-93 PubMed
Am J Respir Crit Care Med. 2003 Jun 15;167(12):1695-703 PubMed
J Immunol. 1988 Aug 1;141(3):1018-25 PubMed
Nature. 1990 Oct 18;347(6294):669-71 PubMed
Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5371-5 PubMed
J Immunol. 1993 Sep 1;151(5):2852-63 PubMed
Am J Respir Cell Mol Biol. 1995 May;12(5):488-96 PubMed
Science. 1995 Oct 13;270(5234):232-3 PubMed
Transplantation. 1996 Jun 27;61(12):1757-62 PubMed
Am J Respir Crit Care Med. 1997 May;155(5):1665-9 PubMed
Eur Respir J. 1997 Jun;10(6):1199-202 PubMed
Eur Respir J. 1997 Jun;10(6):1207-16 PubMed
Am J Respir Crit Care Med. 1997 Nov;156(5):1371-6 PubMed
Am J Respir Cell Mol Biol. 1998 Apr;18(4):526-31 PubMed
Nature. 1998 Apr 9;392(6676):565-8 PubMed
Allergy. 1998 Aug;53(8):749-54 PubMed
J Clin Pharmacol. 1998 Nov;38(11):981-93 PubMed
Am J Respir Crit Care Med. 1999 Feb;159(2):508-11 PubMed
Immunol Cell Biol. 1999 Dec;77(6):469-75 PubMed
